Interviews

Leonard Gomella, MD, physician, professor, and chair of the Department of Urology at Thomas Jefferson University and Clinical Director Jefferson Sidney Kimmel Cancer Network, shares insight on genomic markers in patients with prostate cancer.

Christina Baik, MD, MPH, assistant professor, Seattle Cancer Care Alliance, Thoracic/Head and Neck, Department of Medicine, Division of Medical Oncology, University of Washington, discusses the efficacy of alectinib after first-line crizotinib in patients with ALK-positive lung cancer. Baik says alectinib generally works for about 8 months and is easy to take for patients.